---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-013289"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:38:25.746842+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyclerion CY6463 shows cognition effect size 0.60 in CIAS study; well tolerated

## Summary
- Effect size 0.60 on Cogstate Schizophrenia Battery composite after 14 days of 15 mg CY6463 vs placebo.
- No SAEs, severe AEs, or discontinuations due to AEs; all adverse events transient.
- Favorable changes observed in broad panel of plasma inflammatory biomarkers linked to schizophrenia.
- 48 adults with stable schizophrenia on single atypical antipsychotic; PK linear dose-proportional.
- Company exploring partnerships; webinar July 28 at 8:00 a.m. EDT to discuss data.

## SEC filing metadata
- accession: 0000950170-22-013289
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017022013289/0000950170-22-013289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017022013289/cycn-20220728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-013289
- JSON: https://secwatch.observer/filing/0000950170-22-013289.json
- Plain text: https://secwatch.observer/filing/0000950170-22-013289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.